BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q3 2025 Earnings Call Transcript
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q3 2025 Earnings Call Transcript October 27, 2025BioMarin Pharmaceutical Inc. misses on earnings expectations.
Biomarin Pharmaceutical Inc (BMRN)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Bayforest Capital Theodoros Tsagaris | 7,330 | $396,993 | +69% | 0.19% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $86.75 | 3,625 | $314,468.75 | 10,905 | 2022-10-31 | Filing | |
| $78.84 | 900 | $70,955.37 | 30,740 | 2020-08-31 | Filing | |
| $78.22 | 11,900 | $930,759.69 | 29,840 | 2020-08-31 | Filing | |
| $21.76 | 161 | $3,503.36 | 100,574 | 2012-10-31 | Filing | |
| $21.76 | 548 | $11,924.48 | 15,294 | 2012-10-31 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $59.31 | 1,786 | $105,927.66 | 14,173 | 2025-05-20 | Filing | |
| $64.92 | 273 | $17,723.16 | 32,700 | 2025-05-02 | Filing | |
| $71.52 | 1,295 | $92,618.40 | 16,955 | 2025-03-19 | Filing | |
| $71.28 | 7,034 | $501,355.38 | 87,655 | 2025-03-06 | Filing | |
| $68.38 | 1,344 | $91,902.72 | 13,105 | 2025-02-24 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1,332,398 | $72,162,676 | 0.24% | |
| 2. | 69,530,000 | $66,088,265 | 0.07% | |
| 3. | 935,466 | $50,664,840 | 0.07% | |
| 4. | 713,956 | $38,667,857 | 0.21% | |
| 5. | 35,206,000 | $33,449,046 | 1.14% |
News See All
9 Most Profitable Biotech Stocks to Buy
On October 6, StemPoint Capital CIO Michelle Ross appeared on CNBC’s ‘Closing Bell’ to talk about the biotech space.
Cantor Fitzgerald Reiterates a Buy Rating for BioMarin Pharmaceutical (BMRN)
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the best healthcare stocks with the highest upside.
9 Best Healthcare Stocks with the Highest Upside
Talking about how people are feeling the impact of the shutdown, Dr.
Where is BioMarin Pharmaceutical (BMRN) Headed According to Analysts?
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the best biotech stocks with high potential. BioMarin Pharmaceutical Inc.
14 Biotech Stocks with High Potential
Healthcare was the second worst performer this year, with pharma and biotech companies under pressure.
Growth and Pipeline Keep BioMarin Pharmaceutical Inc. (BMRN) Attractive for Investors
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is among the most promising biotech stocks to buy according to hedge funds. In the second quarter, Tealwood Asset Management Inc.
BioMarin Pharmaceutical Inc. (BMRN) Hits Its 52-Week Low
On September 23, 2025, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) hit a 52-week low, falling 23.7% over the past year to $52.93.
7 Most Promising Biotech Stocks to Buy According to Hedge Funds
If there’s one sector that is gaining popularity each day, it’s definitely the biotechnology market.
Raymond James Maintains a Buy Rating on BioMarin Pharmaceutical (BMRN), Sets a $85 PT
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the best strong buy stocks to invest in according to Wall Street.